Molecular testing in stage I-III non-small cell lung cancer: Approaches and challenges

Area of Science:

• Oncology
• Molecular Biology
• Precision Medicine

Background:

• Precision medicine has advanced targeted therapies for advanced non-small cell lung cancer (NSCLC).
• Routine molecular testing is not standard for early-stage (I-III) NSCLC, which typically involves surgery and chemotherapy or chemoradiotherapy.
• The ADAURA trial investigated adjuvant osimertinib for early-stage NSCLC.

Purpose of the Study:

• To review the implications of integrating molecular testing into the management of stage I-III non-squamous NSCLC.
• To discuss the impact of the ADAURA trial findings on clinical practice.
• To explore challenges and best practices for molecular testing in early-stage NSCLC from pathology, surgical, and oncology perspectives.

Main Methods:

• Review of the phase 3 ADAURA trial data.
• Analysis of the role of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in the adjuvant setting.
• Discussion of clinical implications for molecular testing in early-stage NSCLC.

Main Results:

• Adjuvant osimertinib reduced disease recurrence by 80% in EGFR mutation-positive stage IB-IIIA NSCLC patients post-resection.
• Treatment selection for adjuvant osimertinib requires identification of EGFR-TKI sensitizing mutations.
• Other targeted agents are under evaluation for adjuvant and neoadjuvant settings.

Conclusions:

• The ADAURA trial demonstrates the efficacy of adjuvant targeted therapy in early-stage NSCLC.
• Comprehensive molecular testing will become essential for stage I-III NSCLC management.
• Integrating molecular testing requires coordinated efforts across pathology, surgery, and oncology.